Company research
iBio, Inc.
CIK 1420720Updated Sep 29, 2026
SecurityIBIO · NASDAQ · equity
Name history
iBio, Inc. · through Sep 14, 2026iBioPharma, Inc. · through Aug 14, 2009InB:Biotechnologies, Inc. · through Jul 17, 2008
IBIO price & chart
Loading TradingView…
NASDAQ:IBIO on TradingView ↗About the company
iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.
In the news
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
ARS filing
DEF 14A filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-K filing
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 99,110,000Source | 23,185,000Source | 28,734,000Source | 41,207,000Source |
| Property, Plant and Equipment, NetUSD | 3,086,000Source | 3,163,000Source | 3,632,000Source | 4,219,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 1,825,000Source | 6,848,000Source | 5,368,000Source | 5,388,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 56,395,000Source | 8,582,000Source | 14,210,000Source | 4,301,000Source |
| Inventory, NetUSD | — | — | 0Source | — |
| Assets, CurrentUSD | 92,221,000Source | 9,721,000Source | 15,672,000Source | 26,259,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,078,000Source | 1,034,000Source | 749,000Source | 664,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,667,000Source | 2,051,000Source | 2,401,000Source | 2,722,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 13,397,000Source | 8,305,000Source | 7,410,000Source | 25,826,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | 0Source | — |
| Common Stock, Value, IssuedUSD | 56,000Source | 19,000Source | 9,000Source | 20,000Source |
| Retained Earnings (Accumulated Deficit)USD | -365,268,000Source | -332,224,000Source | -313,847,000Source | -288,940,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -45,000Source | — | — | — |
| Stockholders' Equity Attributable to ParentUSD | 85,713,000Source | 14,880,000Source | 21,324,000Source | 15,381,000Source |
| Additional Paid in Capital, Common StockUSD | 450,970,000Source | 347,085,000Source | 335,162,000Source | 304,301,000Source |
| Liabilities and EquityUSD | 99,110,000Source | 23,185,000Source | 28,734,000Source | 41,207,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,745,000Source | 6,106,000Source | 3,840,000Source | 21,582,000Source |
| Operating Lease, Liability, CurrentUSD | 546,000Source | 490,000Source | 436,000Source | 389,000Source |
| Accounts Payable, CurrentUSD | 4,423,000Source | 2,188,000Source | 358,000Source | 1,849,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,652,000Source | 2,199,000Source | 2,688,000Source | 3,125,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 5,626,000Source | 1,345,000Source | 2,028,000Source | 4,034,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 7,579,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | 0Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -33,044,000Source | -18,377,000Source | -24,907,000Source | -65,010,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,373,000Source | 1,530,000Source | 2,038,000Source | 4,391,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 65,000Source | — | — | -1,000,000Source |
| Increase (Decrease) in Accounts PayableUSD | 2,223,000Source | 1,831,000Source | -1,491,000Source | -625,000Source |
| Deferred Income Tax Expense (Benefit)USD | -6,370,000Source | -8,542,000Source | -5,295,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -23,218,000Source | -15,304,000Source | -18,554,000Source | -30,436,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | 692,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -31,999,000Source | 742,000Source | 906,000Source | 7,009,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 578,000Source | 16,000Source | 210,000Source | 5,738,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 103,048,000Source | 8,929,000Source | 24,494,000Source | 2,301,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | 6,246,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 47,831,000Source | -5,633,000Source | 6,846,000Source | -21,093,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 56,623,000Source | 8,792,000Source | 14,425,000Source | 7,579,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 72,000Source | 212,000Source | 749,000Source | 687,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,373,000Source | 1,530,000Source | 1,975,000Source | 2,863,000Source |
| Amortization of Intangible AssetsUSD | 20,000Source | 20,000Source | 20,000Source | 126,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 7,579,000Source |
| DepreciationUSD | 558,000Source | 484,000Source | 638,000Source | 674,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | 1,000,000Source | — |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | — | — | -4,909,000Source | 773,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 808,000Source | — |
| General and Administrative ExpenseUSD | 10,595,000Source | 10,690,000Source | 11,674,000Source | 19,016,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 5,003,000Source | 0Source | 0Source | 565,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 5,003,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -29,311,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | -18,377,000Source | -15,443,000Source | -29,311,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -9,464,000Source | -35,699,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 53,000Source | 212,000Source | 172,000Source | — |
| Investment Income, InterestUSD | 2,150,000Source | 437,000Source | 363,000Source | 213,000Source |
| Net Income (Loss) Attributable to ParentUSD | -33,044,000Source | -18,377,000Source | -24,907,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -33,044,000Source | — | — | -29,311,000Source |
| Nonoperating Income (Expense)USD | 2,097,000Source | 225,000Source | 1,191,000Source | 32,000Source |
| Operating ExpensesUSD | 35,241,000Source | 19,002,000Source | 16,859,000Source | 29,343,000Source |
| Proceeds from Issuance of Common StockUSD | 3,529,000Source | 3,541,000Source | 25,523,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 10,800,000Source | — | — | 4,100,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 131,000Source | — | 0Source |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total RevenueUSD | 100,000Source | 400,000Source | 225,000Source | 0Source |
| Operating Income (Loss)USD | -35,141,000Source | -18,602,000Source | -16,634,000Source | -29,343,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -33,044,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -33,044,000Source | -18,377,000Source | -24,907,000Source | — |
| Earnings Per Share, BasicUSD per share | -0.32Source | -1.75Source | -6.5Source | -5.31Source |
| Earnings Per Share, DilutedUSD per share | -0.32Source | -1.75Source | -6.5Source | -5.31Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 104,060,000Source | 10,499,000Source | 3,831,000Source | 12,245,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 104,060,000Source | 10,499,000Source | 3,831,000Source | 12,245,000Source |
| Interest Expense (non-operating)USD | 53,000Source | 212,000Source | 172,000Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 20,000Source | 20,000Source | 20,000Source | 126,000Source |
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | 10,595,000Source | 10,690,000Source | 11,674,000Source | 19,016,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -29,311,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | -18,377,000Source | -15,443,000Source | -29,311,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | -1.75Source | -4.03Source | -2.39Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | -1.75Source | -4.03Source | -2.39Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -9,464,000Source | -35,699,000Source |
| Interest ExpenseUSD | — | — | — | 83,000Source |
| Investment Income, InterestUSD | 2,150,000Source | 437,000Source | 363,000Source | 213,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -33,044,000Source | — | — | -29,311,000Source |
| Nonoperating Income (Expense)USD | 2,097,000Source | 225,000Source | 1,191,000Source | 32,000Source |
| Operating ExpensesUSD | 35,241,000Source | 19,002,000Source | 16,859,000Source | 29,343,000Source |
| Research and Development ExpenseUSD | 19,643,000Source | 8,312,000Source | 5,185,000Source | 10,327,000Source |
Filing attachments
ibio-20260914xex99d1.htm · 8-K · 2026-09-14
EX-99.1 2 ibio-20260914xex99d1.htm EX-99.1 Exhibit 99.1 BREAKTHROUGH ANTIBODIES FOR OBESITY AND CARDIOMETABOLIC DISEASES CORPORATE PRESENTATION • September 2026 ─────────────────────────────────────────── Certain statements in this presentation constitute "forward -looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "conti…
Read attachment ↗ibio-20260828xex99d1.htm · 8-K · 2026-08-28
EX-99.1 2 ibio-20260828xex99d1.htm EX-99.1 Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress. “Fiscal year 2…
Read attachment ↗ibio-20260722xex99d1.htm · 8-K · 2026-08-04
EX-99.1 3 ibio-20260722xex99d1.htm EX-99.1 Exhibit 99.1 iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer SAN DIEGO, August 4, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leader…
Read attachment ↗ibio-20260701xex99d1.htm · 8-K · 2026-07-01
EX-99.1 2 ibio-20260701xex99d1.htm EX-99.1 Exhibit 99.1 iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone Full dataset …
Read attachment ↗ibio-20260512xex99d1.htm · 8-K · 2026-05-12
EX-99.1 2 ibio-20260512xex99d1.htm EX-99.1 Exhibit 99.1 iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update Received regulatory clearance to initiate its phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) of its bispecific antibody Reported new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-…
Read attachment ↗ibio-20260507xex99d1.htm · 8-K · 2026-05-08
EX-99.1 2 ibio-20260507xex99d1.htm EX-99.1 Exhibit 99.1 iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors San Diego, California / May 8, 2026 / (GLOBE NEWSWIRE) / -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment of Elizabeth Stoner, M.D., M.S. to its Board of Directors. Dr. Stoner is appointed as an independent member of the Board of Dire…
Read attachment ↗